Select Language

LYPD3

LYPD3 Overview

English Name	Ly6/PLAUR domain-containing protein 3	Approved Drugs	0
Drugs in Clinical Trials	1	Target Synonym	C4.4A，GPI-Anchored Metastasis-Associated Protein Homolog，2310061G07Rik，GPI-Anchored Metastasis-Associated Protein C4.4A Homolog，MIG-C4，UNQ491/PRO1007，Ly6/PLAUR domain-containing protein 3，LYPD3，Matrigel-Induced Gene C4 Protein，LY6/PLAUR Domain Containing 3
Highest Development Stage	Phase 1 Clinical

English Name	Ly6/PLAUR domain-containing protein 3
Target Synonym	C4.4A，GPI-Anchored Metastasis-Associated Protein Homolog，2310061G07Rik，GPI-Anchored Metastasis-Associated Protein C4.4A Homolog，MIG-C4，UNQ491/PRO1007，Ly6/PLAUR domain-containing protein 3，LYPD3，Matrigel-Induced Gene C4 Protein，LY6/PLAUR Domain Containing 3
Approved Drugs	0
Drugs in Clinical Trials	1
Highest Development Stage	Phase 1 Clinical

LYPD3 Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
His Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
LY3-H52H5	Human	HEK293	Human LYPD3 / C4.4A Protein, His Tag

Total: 1

LYPD3 Background

Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.